Form 4: NeueHealth Director Disposes All Shares Post-Merger
Insider Transaction Report
Edward T. Mathers, a director and 10% owner of NeueHealth, Inc., reported the disposition of all his beneficially owned common stock, warrants, and preferred stock on October 2, 2025, following the company's merger into a wholly-owned subsidiary.
Summary
- Edward T. Mathers, a director and 10% owner of NeueHealth, Inc. (NEUE), reported significant changes in his beneficial ownership on October 2, 2025.
- These transactions occurred as a direct result of the merger of NeueHealth, Inc. into NH Holdings Acquisition 2025, Inc., with NeueHealth surviving as a wholly-owned subsidiary of NH Holdings 2025, Inc. (Parent).
- Pursuant to rollover agreements, all shares of Common Stock, Series A Convertible Perpetual Preferred Stock, and Series B Convertible Perpetual Preferred Stock beneficially owned by the reporting person were contributed to NH Holdings 2025 SPV, L.P. (Ultimate Parent) in exchange for limited partnership interests.
- Following this contribution, all such shares of NeueHealth were cancelled and ceased to exist.
- Transactions included the exercise of warrants for common stock at an exercise price of $0.01 per share, followed by cashless net exercises and dispositions.
- The fair market value used for cashless exercises was $6.75 per share, based on the closing market price on October 1, 2025.
- The reporting person disclaims beneficial ownership of securities held indirectly through NEA 17 and NEA 18 VGE, except to the extent of any pecuniary interest.
Sentiment
Score: 5
Explanation: The filing reports the factual outcome of a corporate merger, resulting in the disposition of all beneficially owned securities by a director/10% owner as the company transitioned to a private entity. This is a structural change rather than a performance indicator, making the sentiment neutral for the filing itself.
Positives
- The merger event indicates a strategic corporate action, potentially aimed at restructuring or achieving specific business objectives under new ownership.
- The cashless net exercise of warrants at a fair market value of $6.75 per share indicates value realization for the exercised derivatives prior to the disposition.
Negatives
- The reporting person, a director and 10% owner, disposed of all directly and indirectly beneficially owned common stock, warrants, and preferred stock in NeueHealth, Inc. due to the merger.
- Public shareholders of NeueHealth, Inc. would have had their shares acquired or exchanged as the company became a wholly-owned subsidiary, ceasing its prior public trading status.
Risks
- The company's transition to a wholly-owned subsidiary means it is no longer a publicly traded entity, which alters its governance, reporting requirements, and access to public capital markets.
- Shareholders who did not participate in rollover agreements would have had their shares acquired, potentially at a price that may or may not have met their investment expectations.
Future Outlook
The filing indicates that NeueHealth, Inc. has become a wholly-owned subsidiary of NH Holdings 2025, Inc. following a merger. This implies a transition from a publicly traded entity to a private one, with future operations and strategic direction determined by the new parent company.
Industry Context
The merger of NeueHealth, Inc. into a wholly-owned subsidiary signifies a consolidation within the healthcare or health technology sector. Such transactions often occur to streamline operations, achieve synergies, or facilitate a strategic pivot away from public market pressures, potentially impacting the competitive landscape and market dynamics for remaining public companies in the sector.
Comparison to Industry Standards
- Not applicable for this type of filing, which reports insider transactions following a corporate merger rather than operational or financial performance against industry benchmarks.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure | NeueHealth, Inc. transitioned from a publicly traded company to a wholly-owned subsidiary of NH Holdings 2025, Inc. This fundamentally alters its corporate governance framework, moving from public company oversight to private ownership control. | 10/02/2025 | Significantly reduces public disclosure requirements and shifts governance decisions to the parent company and its limited partners, potentially streamlining decision-making but reducing transparency for former public shareholders. |
Related Party Transactions
- The transactions involve the disposition of securities by Edward T. Mathers, a director and 10% owner, as part of a merger agreement where NeueHealth became a wholly-owned subsidiary. This constitutes a related party transaction due to the reporting person's significant role and ownership stake in the company undergoing the merger.
Stakeholder Impact
- Shareholders: Former public shareholders of NeueHealth, Inc. had their shares acquired or exchanged for limited partnership interests in the Ultimate Parent, ceasing their direct equity ownership in the public entity.
- Management and Employees: The company's transition to a wholly-owned subsidiary may lead to changes in management structure, operational strategies, and employee benefits under the new parent company's direction.
- Customers and Suppliers: May experience changes in business relationships, service offerings, or contractual terms as the company integrates into the parent entity's operations.
Next Steps
- NeueHealth, Inc. will operate as a wholly-owned subsidiary of NH Holdings 2025, Inc.
- The reporting person's investment in NeueHealth, Inc. has been converted into limited partnership interests in NH Holdings 2025 SPV, L.P.
Key Dates
| Date | Description |
|---|---|
| 08/04/2023 | Date of the original Credit Agreement between the Issuer and lenders. |
| 08/29/2023 | Warrants became exercisable as to 828,395 shares. |
| 09/18/2023 | Warrants became exercisable as to 552,263 shares. |
| 10/02/2023 | Date of Incremental Amendment No. 1 to the Credit Agreement. |
| 11/01/2023 | Warrants became exercisable as to 100,606 shares. |
| 12/20/2023 | Warrants became exercisable as to 175,525 shares. |
| 12/23/2024 | Date of the Agreement and Plan of Merger. |
| 04/08/2024 | Date of Incremental Amendment No. 2 to the Credit Agreement. |
| 04/30/2024 | Warrants became exercisable as to 123,729 shares and 371,187 shares. |
| 06/21/2024 | Warrants became exercisable as to 1,733 shares and 28,399 shares; Date of Amendment No. 3 to the Credit Agreement. |
| 10/02/2024 | Warrants became exercisable as to 61,865 shares and 185,595 shares. |
| 10/29/2024 | Date of Amendment No. 4 to the Credit Agreement. |
| 09/26/2025 | Warrants became exercisable as to 1,868 shares and 22,355 shares. |
| 09/30/2025 | Date of the Warrantholders Agreement and Amendment No. 5 to the Credit Agreement. |
| 10/01/2025 | Closing market price of $6.75 per share used for cashless warrant exercises. |
| 10/02/2025 | Date of earliest transaction; Merger effective date; Warrants became fully exercisable; Disposition of all beneficially owned securities. |
| 10/06/2025 | Signature date of the Form 4 filing. |
| 10/02/2030 | Expiration date for certain warrants. |
Keywords
NeueHealth, NEUE, Form 4, Insider Transaction, Merger, Beneficial Ownership, Common Stock, Preferred Stock, Warrants, Corporate Governance, Equity Disposition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.